Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 7-arm NCT04623541

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1)

A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Sponsor: AbbVie

Conditions Relapsed/Refractory Chronic Lymphocytic Leukemia Richter's Syndrome Small Lymphocytic Lymphoma Treatment-naïve High Risk Chronic Lymphocytic Leukemia

Interventions Epcoritamab Lenalidomide Pirtobrutinib Venetoclax rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone

Updated 34 times since 2020 Last updated: Mar 2, 2026 Started: Nov 25, 2020 Primary completion: Dec 31, 2027 Completion: Feb 29, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome, this trial is ongoing. The trial is conducted by AbbVie and has accumulated 34 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

34 versions recorded

Mar 2026 — Present [monthly]

Active Not Recruiting PHASE1/PHASE2
Feb 2026 — Mar 2026 [monthly]

Active Not Recruiting PHASE1/PHASE2

Status: Recruiting → Active Not Recruiting
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE1/PHASE2
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE1/PHASE2
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE1/PHASE2

▶ Show 29 earlier versions

Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE1/PHASE2
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE1/PHASE2
Jun 2025 — Sep 2025 [monthly]

Recruiting PHASE1/PHASE2
May 2025 — Jun 2025 [monthly]

Recruiting PHASE1/PHASE2
Apr 2025 — May 2025 [monthly]

Recruiting PHASE1/PHASE2
Jan 2025 — Apr 2025 [monthly]

Recruiting PHASE1/PHASE2
Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE1/PHASE2
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE1/PHASE2
Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
May 2024 — Jun 2024 [monthly]

Recruiting PHASE1_PHASE2
Apr 2024 — May 2024 [monthly]

Recruiting PHASE1_PHASE2
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE1_PHASE2
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE1_PHASE2
Dec 2023 — Feb 2024 [monthly]

Recruiting PHASE1_PHASE2
Sep 2023 — Dec 2023 [monthly]

Recruiting PHASE1_PHASE2
Jul 2023 — Sep 2023 [monthly]

Recruiting PHASE1_PHASE2
Apr 2023 — Jul 2023 [monthly]

Recruiting PHASE1_PHASE2
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE1_PHASE2
Jul 2022 — Mar 2023 [monthly]

Recruiting PHASE1_PHASE2
Apr 2022 — Jul 2022 [monthly]

Recruiting PHASE1_PHASE2
Feb 2022 — Apr 2022 [monthly]

Recruiting PHASE1_PHASE2
Sep 2021 — Feb 2022 [monthly]

Recruiting PHASE1_PHASE2
Feb 2021 — Sep 2021 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2021 — Feb 2021 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Dec 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Nov 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie
Eli Lilly and Company
Genmab

Data source: Genmab

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Aarhus, Denmark , Amsterdam, Netherlands , Ann Arbor, United States , Badalona, Spain , Barcelona, Spain , Bedford Park, Australia , Bethesda, United States , Birmingham, United States , Bologna, Italy and 66 more locations